Pharmaceutical industry in China

Fosun International's 2021 Annual Report Wins Gold Award at the 2022 International ARC Awards

Retrieved on: 
Friday, January 27, 2023
The Spring Festival, Club Med, Letter, Hospital, Airport authority, Gold Award, Face, Ali Baba, Mainland China, Future, Hang Seng Bank, Commercial bank, NWS Holdings, Gold, China Construction Bank, New Year, CK Hutchison Holdings, Weather, Citigroup, Tablet, Happiness, Pharmaceutical industry in China, Fruit, CLP Group, Investment, HKEX, Photography, Morgan Stanley, Goldman Sachs, New World Development, Spring Festival, International, Annual report, Government, Imperial Bank of China, Accumulation, COVID-19, ARC, The Company, Organization, Vaccination, Film industry, Pharmaceutical industry, Fosun International, China Telecom, Nomura, Silver, Health, Azvudine

The 2021 annual report of Fosun International Limited ("Fosun International" or the "Company", HKEX: 00656) won Gold Award in the "Traditional Annual Report" category of the 2022 International ARC Awards.

Key Points: 
  • The 2021 annual report of Fosun International Limited ("Fosun International" or the "Company", HKEX: 00656) won Gold Award in the "Traditional Annual Report" category of the 2022 International ARC Awards.
  • Hailed as the "Academy Awards of annual reports", the International ARC Awards is the world's most prestigious competition honoring excellence in annual reports.
  • In addition to Fosun International, CK Hutchison Holdings and NWS Holdings also won awards in the Traditional Annual Report - Diversified Business category of the 2022 International ARC Awards.
  • Hailed as the "Academy Awards of annual reports", the International ARC Awards is globally recognized for its openness and fairness, providing a platform for the highest standards in the annual report industry.

Hovione and GEA announce a strategic collaboration to advance Continuous Tableting

Retrieved on: 
Wednesday, December 14, 2022
Laboratory, DAX, Culture, Spray drying, API, MDAX, Food, Plant, CDMO, German, Partnership, Communication, Geas, ESG, Continuity, CO2, Pharmaceutical industry in China, GEA, Growth, Pharmaceutical industry, Engineering, Fine chemical, Hovione

LISBON, Portugal, Dec. 14, 2022 /PRNewswire/ -- Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting.

Key Points: 
  • LISBON, Portugal, Dec. 14, 2022 /PRNewswire/ -- Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting.
  • It combines GEAs engineering expertise with Hoviones development and manufacturing experience and both parties commit to partner to accelerate the adoption of Continuous Tableting technology.
  • In the context of this strategic collaboration, Hovione and GEA will combine their strengths to further advance the technology and contribute to the establishment of new standards and new levels of market acceptance.
  • This collaboration with GEA, gives us the opportunity to link up with a leading designer and supplier of Continuous Tableting equipment solutions and bring Continuous Tableting to the next levels of reliability, flexibility and adoption."

Hovione and GEA announce a strategic collaboration to advance Continuous Tableting

Retrieved on: 
Wednesday, December 14, 2022
Laboratory, DAX, Culture, Spray drying, API, MDAX, Food, Plant, CDMO, German, Partnership, Communication, Geas, ESG, Continuity, CO2, Pharmaceutical industry in China, GEA, Growth, Pharmaceutical industry, Engineering, Fine chemical, Hovione

LISBON, Portugal, Dec. 14, 2022 /PRNewswire/ -- Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting.

Key Points: 
  • LISBON, Portugal, Dec. 14, 2022 /PRNewswire/ -- Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting.
  • It combines GEAs engineering expertise with Hoviones development and manufacturing experience and both parties commit to partner to accelerate the adoption of Continuous Tableting technology.
  • In the context of this strategic collaboration, Hovione and GEA will combine their strengths to further advance the technology and contribute to the establishment of new standards and new levels of market acceptance.
  • This collaboration with GEA, gives us the opportunity to link up with a leading designer and supplier of Continuous Tableting equipment solutions and bring Continuous Tableting to the next levels of reliability, flexibility and adoption."

advanco and Vantage Partner to Offer First Interoperable Pharma Traceability Solution

Retrieved on: 
Wednesday, September 7, 2022
Software, Track, ARC, ERP, Time, Solution, Industry, Vantage, Pharmaceutical industry, Software as a service, Architecture, Medication, Track and trace, Pharmaceutical industry in China, Lists of record labels, Support, Fine chemical, Risk management, Pharma

HILLSBOROUGH, N.J., Sept. 7, 2022 /PRNewswire/ -- Advanco SA today announced that it is partnering with Vantage Solutions to provide the first open, interoperable, and secure traceability solution for the Pharmaceutical Industry.

Key Points: 
  • HILLSBOROUGH, N.J., Sept. 7, 2022 /PRNewswire/ -- Advanco SA today announced that it is partnering with Vantage Solutions to provide the first open, interoperable, and secure traceability solution for the Pharmaceutical Industry.
  • The time is right for advanco and Vantage to jointly offer ARC/QU4RTET as a bundled L3/L4/L5 solution.
  • ARC/QU4RTET is fully integrated to provide the Level 3 ARC platform serialization engine with the Level 4/5 QU4RTET traceability solution.
  • "We are excited to partner with advanco in offering the first open and scalable traceability system for the Pharmaceutical market," said Vantage President John Jordon.

South African Pharmaceutical Industry Market Report 2022: Profiles of 129 Companies including Cipla, Novartis, Johnson & Johnson, Pfizer, Aspen and Adcock Ingram - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 13, 2022
Health, Pharmaceutical, Angus Goodleaf, Department of Trade, Industry and Competition, Competition, COVID-19, Aspen, Radiopharmaceutical, Novartis, Department, Dis-Chem, Growth, Vaccine, Johnson & Johnson, Industry, Cipla, Pharmaceutical industry in China, Pharmaceutical industry, Pfizer

South Africa has the world's largest antiretroviral programme and is one of the major producers of radiopharmaceuticals.

Key Points: 
  • South Africa has the world's largest antiretroviral programme and is one of the major producers of radiopharmaceuticals.
  • Many companies hope to be part of this growth, and there are around 30 licensed commercial cannabis producers in South Africa.
  • This report focuses on the pharmaceutical industry in South Africa including manufacture, retail and wholesale trade in pharmaceuticals and alternative health products, such as medicinal cannabis.
  • There are profiles of 129 companies including international companies Cipla, Novartis, Johnson & Johnson and Pfizer, local companies including Aspen and Adcock Ingram, retailers Clicks and Dis-Chem, and cannabis companies such as Goodleaf.

China Jo-Jo Drugstores Receives 2021 China ESG Golden Awards- Sustainability Award from Sina Finance

Retrieved on: 
Wednesday, December 29, 2021
U.S. Securities and Exchange Commission, China Life Insurance Company, Commercial bank, The Company, Company, COSCO, NASDAQ, Pharmacy, ESG, Pharmaceutical industry in China, CEO, The National German Sustainability Award, Golden Awards, Marketing, Award, COSCO Shipping Holdings, Imperial Bank of China, Security (finance), Social responsibility, Environment, Awareness, Industry, Pharmaceutical industry

HANGZHOU, China, Dec. 29, 2021 /PRNewswire/ --China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that the Company has received 2021 China ESG Golden Awards - Sustainability Award (the "Award") from Sina Finance, indicating that industry experts have acknowledged the Company's awareness and actions of developing sustainability, and they have praised the Company's contributions to corporate social responsibility.

Key Points: 
  • HANGZHOU, China, Dec. 29, 2021 /PRNewswire/ --China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that the Company has received 2021 China ESG Golden Awards - Sustainability Award (the "Award") from Sina Finance, indicating that industry experts have acknowledged the Company's awareness and actions of developing sustainability, and they have praised the Company's contributions to corporate social responsibility.
  • Sina Finance hosts the China ESG Golden Awards to recognize companies with outstanding contributions to sustainability and ESG (ESG stands for "Environment, Society and Governance") performance.
  • The committee of Sina Finance reviews companies through professional and transparent ESG performance evaluation, online voting, and expert review to select and award companies with exceptional ESG performance.
  • The Company is one of the ten notable companies that Sina Finance picked for Sustainability Award in 2021, among well-known companies including COSCO Shipping Holdings, Industrial and Commercial Bank of China, China Life Insurance Company and Shanghai Fosun Pharmaceutical Co., Ltd.
    Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores, commented, "We are very proud to receive the 2021 China ESG Golden Awards - Sustainability Award from Sina Finance, which recognizes our efforts in sustainability and responsible business.

Roche announces the release of its newest artificial intelligence based digital pathology algorithms to aid pathologists in evaluation of breast cancer markers, Ki-67, ER and PR

Retrieved on: 
Tuesday, December 7, 2021
Central nervous system, Risk, Eye, Pathology, Health, Digital, Woman, Breast cancer, Deep learning, Dow Jones, World, List, PMID, Diagnosis, Algorithm, Internet, Medullary breast carcinoma, Joint Medical Service (Germany), Infection, Genentech, Jerri Nielsen, Research, Cancer, Patient, Pharmaceutical industry in China, Biomarker, CHF, Artificial intelligence, AI, DJSI, Name, Software, World Health Organization, Benchmark, ER, SP1, RO, Hoffmann-La Roche, Workflow, Essential medicines, Ophthalmology, IVD, ROG, DAB, Intelligence, RUO, Solution, Marie Cassidy, Medical imaging, Dietary supplement, Fine chemical

These new algorithms complete the Roche digital pathology breast panel of image analysis algorithms.

Key Points: 
  • These new algorithms complete the Roche digital pathology breast panel of image analysis algorithms.
  • "Roche is committed to the expansion of digital pathology solutions to address unmet medical needs and breast cancer diagnostics is a key opportunity area.
  • In December 2021, Roche will be presenting an abstract (# P1-02-17) on our artificial intelligence, deep learning development of our breast panel RUO algorithms at the San Antonio Breast Cancer Symposium, which features the latest research and development on breast cancer research.
  • Whole slide imaging combined with modern artificial intelligence (AI)-based image analysis tools have the potential to transform the practice of pathology.

I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIE

Retrieved on: 
Monday, November 8, 2021
NDA, GMP, Efficiency, Safety, Intellectual property, Cancer, Industry, Private Securities Litigation Reform Act, Hoffmann-La Roche, General manager, U.S. Securities and Exchange Commission, Infection, Terminology, Roche, Technology, World, Pharmaceutical industry in China, Information technology, Joint Medical Service (Germany), Car, COVID-19, Research, China International Import Expo, Forward-looking statement, Form 20-F, Lishui, Risk, Annual report, Twitter, Protein, Cdx, Roche Diagnostics, Company, CHF, LinkedIn, Solution, Degenerative disease, Food, Essential medicines, SEC, Ophthalmology, List, Genentech, DJSI, Dow Jones, Statistics, Central nervous system, Patient, Exhibition, Letter, WeChat, Fine chemical, Video game

Using companion diagnostics can help innovative biotech companies improve R&D efficiency, ensure the effectiveness and safety of drugs, and control R&D costs.

Key Points: 
  • Using companion diagnostics can help innovative biotech companies improve R&D efficiency, ensure the effectiveness and safety of drugs, and control R&D costs.
  • Under this collaboration, the Company and Roche Diagnostics will jointly develop companion diagnostics solutions for the innovative assets under development by I-Mab to accelerate the research and development process of innovative biologics with cutting-edge diagnosis and treatment technologies.
  • "I believe Roche Diagnostics' world-leading CDx technology will complement I-Mab's innovation efforts and accelerate the clinical research and development of our innovative pipeline.
  • "I-Mab is a pioneer in the field of innovative biopharmaceuticals in China, and its globally competitive pipeline is truly impressive," said Richard Yiu, General Manager of Roche Diagnostics China.

Distributors Announce Proposed Opioid Settlement Will Proceed to Next Phase

Retrieved on: 
Saturday, September 4, 2021
Biotechnology, Pharmaceutical, Medical Supplies, Health, FDA, Infectious Diseases, Hospitals, Clinical Trials, Health sciences, Health care, Health, McKesson Corporation, AmerisourceBergen, Cardinal Health, Pharmaceutical industry in China, Healthcare industry, Pharmacy, Pharmaceutical industry, Opioid epidemic in the United States, AmerisourceBergen, Cardinal Health, McKesson Corporation, AMERISOURCEBERGEN, CARDINAL HEALTH, MCKESSON CORPORATION

Under the proposed settlement agreement and process, all U.S. States, territories, and Washington DC were given 30 days to join the settlement, except West Virginia which settled previously with the companies.

Key Points: 
  • Under the proposed settlement agreement and process, all U.S. States, territories, and Washington DC were given 30 days to join the settlement, except West Virginia which settled previously with the companies.
  • After the conclusion of the political subdivision sign-on period, each company will independently determine whether a sufficient number of political subdivisions have joined for the settlement to proceed to implementation.
  • If the conditions are satisfied, the settlement would become effective 60 days after the distributors determine that there is sufficient participation to proceed.
  • During this 60-day period, the participating states and the distributors would cooperate to obtain consent judgments in each participating state embodying the terms of the settlement.

Dr. Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)

Retrieved on: 
Saturday, September 4, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Health sciences, Health care, Health, NIFTY 50, Pharmaceuticals policy, Dr. Reddy's Laboratories, Pharmacy, Forward-looking statement, Reddy, Pharmaceutical industry in China, Eisai, Cutaneous T cell lymphoma

Further, Dr. Reddys will receive certain sales-based milestones and tiered earn-out payments.

Key Points: 
  • Further, Dr. Reddys will receive certain sales-based milestones and tiered earn-out payments.
  • In March 2016, Dr. Reddys had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co. Ltd.
    Erez Israeli, Chief Executive Officer, Dr. Reddys, said: Addressing unmet patient needs in oncology remains a prime focus area for us.
  • E7777 has significant potential as an important component of systemic therapy for CTCL and other cancers.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.